Strategic Portfolio Management in Cell & Gene

Co-authored by Anshul Mangal, President, and John Khoury, Executive Vice President

Cell and gene therapy is a dynamic field requiring astute strategic portfolio management for capitalizing on opportunities and driving growth. With an impressive $11.7 billion in investments in 2023 and all indictors pointing to accelerated market growth in the coming years, navigating this highly competitive sector requires informed portfolio management decisions.

The groundswell of investment in cell and gene is promising news for patient populations with conditions that have been historically unmet. However, success in bringing novel therapies to market relies on informed portfolio management decisions.

Our Precision for Medicine experts advise that while opportunity for investment is plentiful with more than 1,800 ongoing clinical trials, strategic portfolio assessments and management is critical to success.

Read more about how our experts advise navigating this highly competitive sector in "Portfolio Management Strategies for Growth and Impact in Cell and Gene", published in MedCity News. Subscription required.

About Project Farma

Project Farma, a Precision for Medicine company, specializes in providing comprehensive biomanufacturing strategies and execution services. We have successfully industrialized over 10 commercial cell, gene, and novel therapies, executed 60+ facility builds and capital expansions, and managed $6B+ in technical operations capital investments.

With expertise spanning startups, leading life science corporations, advanced therapy organizations, universities, hospitals, government agencies, and more, our team delivers proven technical operations and manufacturing solutions that shorten time-to-market, helping patients in need.

Visit our website to learn more about Project Farma and how Precision for Medicine’s integrated capabilities — across labs, clinical trials, manufacturing, and data intelligence— can help your organization bring therapies to life.